ID: ALA2323935

Max Phase: Preclinical

Molecular Formula: C28H34Cl2N6O

Molecular Weight: 541.53

Molecule Type: Small molecule

Representations

Canonical SMILES:  CC(C)Nc1nc2c(C(=O)N(C)C)c(Cl)c(Cl)cc2n1C1CCN(c2ccc(C(C)(C)C#N)cc2)CC1

Standard InChI:  InChI=1S/C28H34Cl2N6O/c1-17(2)32-27-33-25-22(15-21(29)24(30)23(25)26(37)34(5)6)36(27)20-11-13-35(14-12-20)19-9-7-18(8-10-19)28(3,4)16-31/h7-10,15,17,20H,11-14H2,1-6H3,(H,32,33)

Standard InChI Key:  VQMVPKAEWRRWNJ-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 541.53

Molecular Weight (Monoisotopic): 540.2171

AlogP: 6.51

#Rotatable Bonds: 6

Polar Surface Area: 77.19

Molecular Species: NEUTRAL

HBA: 6

HBD: 1

#RO5 Violations: 2

HBA (Lipinski): 7

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 2

CX Acidic pKa:

CX Basic pKa: 5.59

CX LogP: 5.63

CX LogD: 5.63

Aromatic Rings: 3

Heavy Atoms: 37

QED Weighted: 0.39

Np Likeness Score: -1.21

References

1. Hilfiker MA, Hoang TH, Cornil J, Eidam HS, Matasic DS, Roethke TJ, Klein M, Thorneloe KS, Cheung M..  (2013)  Optimization of a Novel Series of TRPV4 Antagonists with In Vivo Activity in a Model of Pulmonary Edema.,  4  (2): [PMID:24900661] [10.1021/ml300449k]

2. Brooks CA, Barton LS, Behm DJ, Brnardic EJ, Costell MH, Holt DA, Jolivette LJ, Matthews JM, McAtee JJ, McCleland BW, Patterson JR, Pero JE, Rivero RA, Roethke TJ, Sanchez RM, Shenje R, Terrell LR, Lawhorn BG..  (2019)  Discovery of GSK3527497: A Candidate for the Inhibition of Transient Receptor Potential Vanilloid-4 (TRPV4).,  62  (20): [PMID:31532662] [10.1021/acs.jmedchem.9b01247]

3. Lawhorn BG, Brnardic EJ, Behm DJ..  (2020)  Recent advances in TRPV4 agonists and antagonists.,  30  (8): [PMID:32063431] [10.1016/j.bmcl.2020.127022]

Source

Source(1):

• Scientific Literature